th August 2022 Steve Williams Lead Clinical Pharmacist PrescQIPP Practice Plus Osanlou R Walker L Hughes DA et al Adverse drug reactions multimorbidity and polypharmacy a prospective analysis of 1 month of medical admissions BMJ Open ID: 1032504
Download Presentation The PPT/PDF document "Practice Plus Webinar 17" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. Practice Plus Webinar17th August 2022 Steve WilliamsLead Clinical Pharmacist PrescQIPP Practice Plus
2. Osanlou R, Walker L, Hughes DA, et al. Adverse drug reactions, multimorbidity andpolypharmacy: a prospective analysis of 1 month of medical admissions. BMJ Open2022;12:e055551. doi:10.1136/bmjopen-2021-055551
3.
4.
5. Pirmohamed ADR Hospital Admission studies : Medicines implicated
6. HypertensionAlison WarrenConsultant Pharmacist CardiologyNHS Sussex and University Hospitals Sussex
7.
8.
9. Diagnosis of hypertension
10.
11. Treat to Target
12. Guidelines for Pharmacological ManagementUK guidelines from NICE (2019)Also guidelines from other countries/societies :E.g. European Society Cardiology, American Heart Association…….
13. First Line Treatments ACDACEI or ARBCalcium channel blockersThiazide- like DiureticBut don’t forget co-morbidities may affect target and/or treatment choices
14. MonitoringAttainment of BP targetCheck adherenceTitration or intensification of treatmentSide effects from medicinesACEI/ARB : RF and electrolytes angio-oedemaCCB : peripheral oedemaThiazide diuretics : RF and electrolytes Management of postural hypotension
15. NICE Hypertension – NEXT STEPS
16. Cardio-vascular Risk AssessmentCVD risk assessment may affect decisions on offering blood pressure-lowering treatment for stage 1 hypertension.If primary prevention : Follow the NICE guidelines for cardiovascular disease- risk assessment and reduction, including lipid modification (2014 – currently under review) Q-risk tool most commonly used – UK based tool Where possible use most up-to-date version
17. Finding Your Patients – for diagnosis and managementNew diagnosis NHS Health checksOpportunisticCommunity teams – including community pharmaciesLong term condition reviewCodingSearch of clinical systems in GP surgery either directlyfrom clinical system or using tools such as Arden'sPrioritisation of current cohort for managementGP practice system (e.g. EMIS, Systm1 Vision), Arden's.. UCL Partners Proactive Care Framework
18. PHE Data-Pack: Fingertips
19.
20. In summaryIdentification and treatment of high blood pressure key in CVD prevention but Many patients with high blood pressure are undiagnosed We need to do better in treating to target – lifestyle + pharmacologicalMany opportunities for the pharmacy teamPatients have an important role to play